News

For Immediate Release: March 5, 2015

Contact
Mary Kuramoto
513-579-9911 x2523
m.kuramoto@medpace.com

Dr. Franklin O. Smith Keynote Speaker at Leukemia and Lymphoma Society Program: “No Progress without Clinical Trials”

CINCINNATI, OH — (March 5, 2015) –Dr. Franklin O. Smith, III, MD will be a keynote speaker at the Leukemia and Lymphoma Society’s program for blood cancer patients on March 14 in Cincinnati, OH. The complimentary day-long program, “New Paths to Treatment and Hope for Blood Cancers,” is designed to help blood cancer patients and their families learn about managing disease and treatment side effects and new treatments on the horizon. Dr. Smith, Vice President Medical Affairs for oncology at Medpace, will discuss the importance of clinical research in hematology in his session titled: No Progress without Clinical Trials.

Medpace, a global drug and medical device Clinical Research Organization (CRO), is known for its strong therapeutic and regulatory expertise across key therapeutic areas including oncology. Dr. Smith is an industry leader in hematologic malignancies, stem cell transplantation, bone marrow failure syndromes, and childhood cancers. In addition to being a pioneer in hematologic oncology and cord blood transplantation, he is highlyregarded author, speaker, and industry participant.

About Dr. Franklin O. Smith, III, MD

Dr. Frank Smith received his MD degree from the University of South Carolina School of Medicine and completed post-doctoral training in pediatrics at the University of Florida and fellowship training in pediatric hematology/oncology at the University of Washington and the Fred Hutchinson Cancer Research Center. Prior to joining Medpace, Dr. Smith was instrumental in helping build two prestigious stem cell transplant programs at both the University of Cincinnati Cancer Institute and at Riley Hospital for Children at Indiana University. He also was the Clinical Director of the University of Cincinnati Cancer Institute, Director of the Division of Hematology/Oncology at Cincinnati Children’s Hospital Medical Center, and Vice-Chair of the Children’s Oncology Group. He is an adjunct Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine, and has had over 170 scientific manuscripts, reviews, editorials, chapters and books. Dr. Smith is active with various national and international committees and societies in the field of research and clinical care, including serving on the local and national boards of the Leukemia and Lymphoma Society, Chair of the Board of Managers for the Foundation for the Accreditation of Cellular Therapy (FACT) Consulting Services, faculty for the ASCO/AACR Clinical Cancer Research Workshop and as a member of the NCI’s Central Institutional Review Board. Dr. Smith has also served on ad-hoc committees for the FDA including Special Emphasis Panels for Orphan Products Development.

ABOUT MEDPACE

Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions – North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information visit the Medpace website at: www.medpace.com.